Tasso

Tasso is a private company pioneering patient-centric, decentralized blood collection. Its core technology platform consists of compact, lancet-based devices (Tasso+ and Tasso Mini) that enable easy, virtually painless self-collection of liquid blood samples at home, which are then shipped to a lab via an integrated logistics platform. The company targets decentralized clinical trials, remote patient monitoring, and direct-to-consumer diagnostics, aiming to improve patient access, engagement, and retention by removing the barrier of painful, inconvenient traditional blood draws. Tasso is backed by strong scientific validation, with its devices cited in over 100 peer-reviewed publications.

Proprietary lancet-based devices (Tasso+, Tasso Mini) for patient-administered, virtually painless at-home collection of liquid whole blood samples, integrated with an end-to-end logistics and digital platform for sample shipping, tracking, and proctoring.

Tasso competes in the alternative blood collection space against traditional dried blood spot cards and newer microsampling devices (e.g., Neoteryx's Mitra). Its primary differentiation is the collection of liquid whole blood (compatible with standard lab assays) and a strong focus on a painless, hidden-lancet patient experience. Broader competition includes efforts to develop completely non-invasive blood monitoring technologies.